News and Events

Mr. Su Cheng-Fu Successfully Defends Ph.D. Thesis on Novel Mechanism of Chinese Medicine Compound (-)Schisandrin B for Parkinson’s Disease Treatment

September 04, 2024

Prof. Li Min’s research postgraduate student, Mr. Su Chengfu, from the Mr. & Mrs. Ko Chi Ming Centre for Parkinson's Disease Research in School of Chinese Medicine, successfully passed his Ph.D. thesis oral examination on August 6, 2024. His research revealed a novel mechanism by which (-)Schisandrin B (Sch B) exerts a neuroprotective effect in Parkinson's Disease by targeting the ATG16L1/NLRP3 signaling pathway. This suggests that (-) Sch B may be a promising therapeutic drug for PD treatment. The research team is eager to further develop this compound as a clinically competitive therapeutic agent for PD patients.

1725415841183744 1725415841183744
Mr. SU Chengfu and the oral examination board members. (Top row: Left to right): Dr. Chong Wai-po, Associate Professor, School of Chinese Medicine, Hong Kong Baptist University; Prof. Zhao Yan-Xiang, Assoc. Head (ABCT) , DLTC Chair & Professor, Faculty of Science, Hong Kong Polytechnic University; Prof. Shen Han-Ming, Associate Dean (Teaching), Chair Professor, Faculty of Health Sciences, University of Macau. (Middle row: Left to right): Prof. Li Min, Mr. Su Chengfu’s principal supervisor, Executive Associate Dean, Ma Pak Leung Endowed Professor in Innovative Neuromedicine, School of Chinese Medicine, Hong Kong Baptist University; Dr. Xu Jun, Assistant Professor, School of Chinese Medicine, Hong Kong Baptist University; Mr. Su Cheng-Fu (Bottom row): Prof. Yu Zhi-Ling, Professor, School of Chinese Medicine, Hong Kong Baptist University.